Trial reportEuropean journal of applied physiology2007
Prolonged administration of recombinant human erythropoietin increases submaximal performance more than maximal aerobic capacity.
Trial report in European journal of applied physiology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- The relationship between hemoglobin andPloS one · 2023Pooled it
- Effect of erythropoietin on athletic performance: a systematic review and meta-analysis.BMJ open sport & exercise medicine · 2020Pooled it
- Erythropoietin doping in cycling: lack of evidence for efficacy and a negative risk-benefit.British journal of clinical pharmacology · 2013Pooled it
- Moderate hypoxic exposure for 4 weeks reduces body fat percentage and increases fat-free mass in trained individuals: a randomized crossover study.Sleep & breathing = Schlaf & Atmung · 2023Trial
- Enhancement of Exercise Performance by 48 Hours, and 15-Day Supplementation with Mangiferin and Luteolin in Men.Nutrients · 2019Trial
- RhEPO improves time to exhaustion by non-hematopoietic factors in humans.European journal of applied physiology · 2016Trial
- Satellite cell response to erythropoietin treatment and endurance training in healthy young men.The Journal of physiology · 2016Trial
- Autologous Doping with Cryopreserved Red Blood Cells - Effects on Physical Performance and Detection by Multivariate Statistics.PloS one · 2016Trial
- Recombinant erythropoietin in humans has a prolonged effect on circulating erythropoietin isoform distribution.PloS one · 2014Trial
- Haemoglobin mass and running time trial performance after recombinant human erythropoietin administration in trained men.PloS one · 2013Trial
- Current markers of the Athlete Blood Passport do not flag microdose EPO doping.European journal of applied physiology · 2011Trial
- Time to exhaustion at maximal lactate steady state is similar for cycling and running in moderately trained subjects.European journal of applied physiology · 2009Trial
- Metabolomic responses are more sensitive in muscle than serum following 28 days of arduous exercise with erythropoietin administration.Experimental physiology · 2026Article
- Evaluating Transcriptomic Biomarkers for rHuEPO Detection: Assessing the Impact of Exercise and Altitude Exposure.Drug testing and analysis · 2026Article
- Safety Implications of Off-Label Medication Use in Athletes: A Narrative Review.Medicines (Basel, Switzerland) · 2024Review
- Exogenous erythropoietin increases hematological status, fat oxidation, and aerobic performance in males following prolonged strenuous training.Physiological reports · 2024Article
- A century of exercise physiology: key concepts on coupling respiratory oxygen flow to muscle energy demand during exercise.European journal of applied physiology · 2022Review
- Altitude and Erythropoietin: Comparative Evaluation of Their Impact on Key Parameters of the Athlete Biological Passport: A Review.Frontiers in sports and active living · 2022Review
- Transcriptomic Markers of Recombinant Human Erythropoietin Micro-Dosing in Thoroughbred Horses.Genes · 2021Article
- An Abductive Inference Approach to Assess the Performance-Enhancing Effects of Drugs Included on the World Anti-Doping Agency Prohibited List.Sports medicine (Auckland, N.Z.) · 2021Review
Corrections and comments
- Commented on by
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The effects of recombinant human erythropoietin (rHuEpo) treatment on aerobic power (VO2max) are well documented, but little is known about the effects of rHuEpo on submaximal exercise performance. The present study investigated the effect on performance (ergometer cycling, 20-30 min at 80% of maximal attainable workload), and for this purpose eight subjects received either 5,000 IU rHuEpo or placebo every second day for 14 days, and subsequently a single dose of 5,000 IU/placebo weekly/10 weeks. Exercise performance was evaluated before treatment and after 4 and 11 weeks of treatment. With rHuEpo treatment VO2max increased (P<0.05) by 12.6 and 11.6% in week 4 and 11, respectively, and time-to-exhaustion (80% VO2max) was increased by 54.0 and 54.3% (P<0.05) after 4 and 11 weeks of treatment, respectively. However, when normalizing the workload to the same relative intensity (only done at time point week 11), TTE was decreased by 26.8% as compared to pre rHuEpo administration. In conclusion, in healthy non-athlete subjects rHuEpo administration prolongs submaximal exercise performance by about 54% independently of the approximately 12% increase in VO2max.
Indexed as
Identifiers
17668232What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.